Somaia Mohamed, MD, PhD
Associate Professor of PsychiatryCards
About
Research
Publications
2023
Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial.
Zisook S, Moutier C, Rush A, Johnson G, Tal I, Chen P, Davis L, Hicks P, Wilcox J, Planeta B, Lauro K, Scrymgeour A, Kasckow J, Mohamed S. Effect of next-step antidepressant treatment on suicidal ideation: findings from the VAST-D trial. Psychological Medicine 2023, 54: 1172-1183. PMID: 37859623, DOI: 10.1017/s0033291723003008.Peer-Reviewed Original ResearchMajor depressive disorderNext-step treatmentsLifetime suicidal ideationSuicidal ideationSuicide riskLower positive mental healthPrevalence of SISevere depressive episodeAcute treatment periodCurrent MDD episodeBaseline suicidal ideationMore childhood adversitiesSuicide prevention interventionsRisk of SICurrent suicidal ideationAntidepressant treatmentMost patientsInitial medicationMDD episodeMedication treatmentDepressive episodeDepressive disorderTreatment periodDepression trialsPrevention interventionsFactors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes Trial Report
Hicks P, Sevilimedu V, Johnson G, Tal I, Chen P, Davis L, Vertrees J, Zisook S, Mohamed S. Factors Affecting Antidepressant Response Trajectories: A Veterans Affairs Augmentation and Switching Treatments for Improving Depression Outcomes Trial Report. Psychiatric Research And Clinical Practice 2023, 5: 131-143. PMID: 38077276, PMCID: PMC10698706, DOI: 10.1176/appi.prcp.20230017.Peer-Reviewed Original ResearchGroup-based trajectory modelingBaseline depressionEarly improvementSwitching treatmentSingle-blind trialHigher baseline depressionDepression symptom changeAdditional exploratory analysesAssociation of treatmentMajor depressive disorderLogistic regression analysisDepression Outcomes studyDemographic factorsMultinomial logistic regression analysisSpecific depression symptomsExploratory analysisProbability of responseAntidepressant trialsSeverity scoreDepressive disorderTrial reportsOutcome studiesBaseline anxietyPrimary analysisTreatment interventions
2022
Childhood adversity and adulthood major depressive disorder
Zisook S, Planeta B, Hicks PB, Chen P, Davis LL, Villarreal G, Sapra M, Johnson GR, Mohamed S. Childhood adversity and adulthood major depressive disorder. General Hospital Psychiatry 2022, 76: 36-44. PMID: 35366613, DOI: 10.1016/j.genhosppsych.2022.03.008.Peer-Reviewed Original ResearchConceptsMajor depressive disorderChildhood adversityDepressive disorderSuicidal ideationLower remission rateLower depression severityDepression Outcomes studyMore lifetime episodesGOV IDENTIFIERRemission rateClinical featuresClinical outcomesSevere depressionTreatment strategiesLifetime episodesOutcome studiesDepression severitySwitching treatmentYounger ageSecondary analysisComorbid PTSDChildhood maltreatmentWorse qualitySpecific typesDisordersThe Impact of Mental Health Intensive Case Management on Functioning and Clinical Outcomes of Older Black and White Veterans With Serious Mental Illness
Browne J, Mohamed S. The Impact of Mental Health Intensive Case Management on Functioning and Clinical Outcomes of Older Black and White Veterans With Serious Mental Illness. American Journal Of Geriatric Psychiatry 2022, 30: 1183-1194. PMID: 35365385, DOI: 10.1016/j.jagp.2022.02.009.Peer-Reviewed Original ResearchConceptsSerious mental illnessIntensive case managementAnxiety/depressionClinical outcomesWhite veteransBlack veteransUse disordersMental illnessMental health recovery programsCase managementNational program evaluation dataDrug use disordersVeterans Health Administration programHigh-intensity servicesAlcohol use disorderSubstance use treatmentWhite older adultsGreater improvementService deliveryMedication managementBaseline differencesOutcome measuresSociodemographic factorsEqual-access settingSecondary analysis
2021
Evaluation of disparities in impact of mental health intensive case management on 6-month symptoms, functioning, and quality of life between black and white veterans diagnosed with schizophrenia
Browne J, Mohamed S. Evaluation of disparities in impact of mental health intensive case management on 6-month symptoms, functioning, and quality of life between black and white veterans diagnosed with schizophrenia. Schizophrenia Research 2021, 253: 68-74. PMID: 34247886, DOI: 10.1016/j.schres.2021.07.002.Peer-Reviewed Original ResearchConceptsEqual-access health care systemVeterans Health AdministrationWhite veteransHealth care systemClinical characteristicsClinical historySystem involvementMental health recovery programsCare systemService delivery differencesNational program evaluation dataSix-month changesEvaluation of disparitiesIntensive case managementQuality of lifeSubstantial health disparitiesMajority of outcomesJustice system involvementBaseline characteristicsClinical outcomesClinic settingService useSociodemographic factorsHealth AdministrationHealth disparitiesRates and Correlates of Suicidality in VA Intensive Case Management Programs
Mohamed S. Rates and Correlates of Suicidality in VA Intensive Case Management Programs. Community Mental Health Journal 2021, 58: 356-365. PMID: 33948867, DOI: 10.1007/s10597-021-00831-8.Peer-Reviewed Original ResearchConceptsIntensive case management servicesLogistic regression analysisCorrelates of suicidalityCase management servicesProgram entryMultivariable logistic regression analysisSuicidal behaviorIntensive case management programRates of suicidalityQuality of lifeCase management programRegression analysisChi-square testNational program evaluationClinical characteristicsBrief Symptom InventoryIndependent correlatesSubjective symptomsCrisis intervention servicesGreater receiptSquare testSymptom InventoryAdmissionSuicidalityIntervention services
2020
Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment‐resistant major depressive disorder: A VAST‐D report
Zisook S, Johnson G, Hicks P, Chen P, Beresford T, Michalets J, Rao S, Thase M, Wilcox J, Sevilimedu V, Mohamed S. Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment‐resistant major depressive disorder: A VAST‐D report. Depression And Anxiety 2020, 38: 185-195. PMID: 33225492, DOI: 10.1002/da.23114.Peer-Reviewed Original ResearchConceptsDepressive symptom severityContinuation treatmentBupropion SRTreatment outcomesTreatment-resistant major depressive disorderSymptom severitySignificant differential treatment effectsContinuation treatment phaseAcute-phase treatmentAbnormal laboratory valuesLower relapse rateMajor depressive disorderQuality of lifeLess anxietyDifferential treatment effectsMore somnolenceDry mouthRelapse rateExtrapyramidal effectsFull remissionWeek 12Continuation phaseTreatment attemptsDepressive disorderLaboratory valuesStages of major depressive disorder and behavioral multi-morbidities: Findings from nationally representative epidemiologic study
Rhee TG, Mohamed S, Rosenheck RA. Stages of major depressive disorder and behavioral multi-morbidities: Findings from nationally representative epidemiologic study. Journal Of Affective Disorders 2020, 278: 443-452. PMID: 33010569, DOI: 10.1016/j.jad.2020.09.081.Peer-Reviewed Original ResearchConceptsChronic major depressive disorderMajor depressive disorderNew-onset major depressive disorderOnset major depressive disorderBorderline personality disorderDepressive disorderUse disordersRepresentative cross-sectional surveyRepresentative epidemiologic studyPersonality disorderMore psychiatric disordersSubstance use disordersAlcohol use disorderNational Epidemiologic SurveyRelated Conditions-IIICross-sectional surveyDSM-5 diagnostic criteriaMultivariable analysisGroup of adultsEpidemiologic studiesUS adultsDiagnostic criteriaPsychiatric disordersEpidemiologic SurveyMDD historyImpact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial.
Mohamed S, Johnson GR, Sevilimedu V, Rao SD, Hicks PB, Chen P, Lauro K, Jurjus G, Pilkinton P, Davis L, Wilcox JA, Iranmanesh A, Sapra M, Aslam M, Michalets J, Thase M, Zisook S. Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32603560, DOI: 10.4088/jcp.19m13038.Peer-Reviewed Original ResearchConceptsConcurrent posttraumatic stress disorderMajor depressive disorderPosttraumatic stress disorderDepressive disorderVeterans Health Administration medical centersNonpsychotic major depressive disorderStress disorderMini International Neuropsychiatric InterviewAdequate antidepressant treatmentPoor overall outcomeDepressive Symptomatology-Clinician RatedSevere depressive symptomsAntipsychotic augmentationInitial remissionAntidepressant treatmentSuboptimal responseAntipsychotic aripiprazoleCurrent antidepressantsAntidepressant trialsQuick InventoryNeuropsychiatric InterviewClinical trialsMedical CenterRemissionDepressive symptoms
2019
Predictability of Nonremitting Depression After First 2 Weeks of Antidepressant Treatment: A VAST‐D Trial Report
Hicks P, Sevilimedu V, Johnson G, Tal I, Chen P, Davis L, Vertrees J, Mohamed S, Zisook S. Predictability of Nonremitting Depression After First 2 Weeks of Antidepressant Treatment: A VAST‐D Trial Report. Psychiatric Research And Clinical Practice 2019, 1: 58-67. PMID: 36101874, PMCID: PMC9176018, DOI: 10.1176/appi.prcp.20190003.Peer-Reviewed Original ResearchNegative predictive valuePositive predictive valueEarly improvementWeek 2Antidepressant therapyAntidepressant treatmentPredictive valueSingle-blind trialDepressive Symptomatology-Clinician RatedMajor depressive disorderDepression Outcomes studyWeek 12Medication interventionsQuick InventoryDepressive disorderWeek 6Trial reportsOutcome studiesTreatment groupsDegree of improvementSwitching treatmentClinical decisionSecondary analysisRemissionMinimal improvement
News
News
- April 27, 2023
Yale Researcher Awarded $40 Million to Lead New VA Study to Evaluate Esketamine for Treatment Resistant Depression
- July 17, 2017Source: Augmentation With Aripiprazole Found Superior When MDD Patients Don't Respond
Augmentation With Aripiprazole Found Superior When MDD Patients Don't Respond
- July 11, 2017
Next step in depression treatment? Add rather than switch
- September 12, 2016
Yale study analyzes treatment patterns for PTSD